HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.